Hong Kong Laureate Forum: Calling Outstanding Young Scientists in Astronomy, Life Science and Medicine, and Mathematical Sciences!
14.9.2020 04:00:00 EEST | Business Wire | Press release
Open application for the inaugural Hong Kong Laureate Forum starts today and will end on 13 December 2020. We welcome undergraduates, postgraduates and PhD graduates who are aged 35 or below and studying or conducting research in Astronomy, Life Science and Medicine, Mathematical Sciences or other closely related subjects to apply for the Hong Kong Laureate Forum and become one of the 200 selected young scientists to be inspired by world-renowned Shaw Laureates. Eligible Young Scientists are welcome to complete and submit their applications via this link: https://hklaureateforum.org/en/application-form
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200913005003/en/
Open Application from 14 September to 13 December 2020 (Graphic: Business Wire)
The inaugural Hong Kong Laureate Forum will be held on 15-20 November 2021 in Hong Kong. Being Asia’s world city and a city long celebrated for its vibrancy, Hong Kong is an ideal place for such an international gathering.
During a week-long programme, there will be ample opportunities for exchanges between participating Shaw Laureates and the young scientists. Apart from plenary lectures, panel discussions and parallel group sessions conducted by Shaw Laureates and other distinguished scientists, the programme will also offer informal and cozy gatherings with plenty of chances of networking and dialogues. There will also be presentation sessions for selected young scientists to showcase their latest research ideas to spark intellectual exchanges.
Mrs DO PANG Wai Yee, Secretary-General of the Council of the Hong Kong Laureate Forum (the HKLF) said: “As of today, we have received positive response from over 20 Shaw Laureates, including several Nobel Laureates and Fields Medalist, to join our Forum.”
Professor Steven Balbus, Shaw Laureate in Astronomy 2013 remarked: “I have nothing but pleasant memories of Hong Kong and I look forward to many more. It’s a city that feels exciting and that things are working. I think the Hong Kong Laureate Forum is going to be extremely exciting and a very special program that’s going to capture the imagination of the public.”
Professor Simon White, Shaw Laureate in Astronomy 2017 said: “I think the significance of the Shaw Prize is because it makes certain aspects of science visible to a wider public. And this fuels the curiosity which leads people to do science, which pushes them to improve their capabilities. I hope the Hong Kong Laureate Forum will make young people really enthusiastic and curious about science.”
The most outstanding 200 young scientists will be selected to join the inaugural Forum by a Scientific Review Panel comprising local and non-local academics. All applicants, either successful or not, will receive email notification in April 2021.
For enquiries regarding application, please contact Forum Programmes and Participants Enquiry at programme@hklaureateforum.org.
Background
The Hong Kong Laureate Forum is an annual scientific exchange event organized by the HKLF. It aspires to be a world-class academic exchange event to connect the current and next generations of leaders in scientific pursuit. The Forum also promotes understanding and interests of the young generation in Hong Kong and around the world in various disciplines in science and technology. The HKLF was launched in May 2019 and is fully sponsored by Lee Shau Kee Foundation. The important partner of the HKLF is The Shaw Prize Foundation which organizes the annual international award The Shaw Prize.
To the Press
With this press release, we would like to extend an invitation to the Press to attend and report on the inaugural Hong Kong Laureate Forum.
Website:
https://www.hklaureateforum.org
Facebook:
https://www.facebook.com/HKLaureateForum
Twitter:
https://www.twitter.com/HKLaureateForum
Weibo:
https://www.weibo.com/hklaureateforum
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200913005003/en/
Contact information
Forum Programmes and Participants Enquiry
Koji Ho
programme@hklaureateforum.org
Tel: (852) 2905 6505
Media Enquiry
Kelvin Chau
media@hklaureateforum.org
Tel: (852) 2905 6506
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom